Download - CEGEDIM © copyright 2007 – this document should not be distributed without CEGEDIM authorisation
CEGEDIM © copyright 2007 – this document should not be distributed without CEGEDIM authorisation
CHARAKTERISTIKA STUDIE
TOPIC: Treatment of patients with diarrhoea, Smecta.
TIME OF RESEARCH: October-November 2007
TARGET GROUP: pediatrics
SAMPLING POINTS: whole Czech Republic
METHODOLOGY: face to face interviewing
SAMPLING METHOD: stratified random sampling
SOURCE OF ADDRESSES: Cegedim Strategic Data
TOTAL NUMBER OF QUESTIONNAIRES: 98
QUESTIONNAIRE: prepared by Cegedim Strategic Data on the assignment of Ipsen
PROJECT MANAGER, DATA ANALASIS: Dan Hrdlička Lukáš Pertl
Cegedim CZ, Cegedim Strategic Data 2007
Q. 1: Will you estimate how many patients with diarrhoea do you monthly meet in your practice on the average.
Ipsen – Medibus PED4
average number of patients per month median – the middle value
(base for average – total sample)NTOT = 98, NLC = 36, NMC = 39, NBC = 23
Cegedim CZ, Cegedim Strategic Data 2007
Q. 2: Which preparation is usually your first choice anti-diarrhoeal? (the most often named)
(% base – total sample)NTOTAL = 98, NLC = 36, NMC = 39, NBC = 23
Ipsen – Medibus PED4
TOTAL LITTLE CITY MIDDLE CITY BIG CITY
Cegedim CZ, Cegedim Strategic Data 2007
Q. 3A: Why is Smecta your first choice anti-diarrhoeal? Which are its main advantages, strong points?
(most often named)
(% base – Smecta is first choice anti-diarrhoeal)NTOTAL = 64
Ipsen – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007
Q. 3B: Why is Hylak your first choice anti-diarrhoeal? Which are its main advantages, strong points?
(most often named)
(% base – Hylak is first choice anti-diarrhoeal)NTOTAL = 27
Ipsen – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007Ipsen – Medibus PED4
Q. 4: Do you currently prescribe or recommend to your patients also Smecta?
(% base – total sample)NTOT = 98
yes, I prescribe / I recommend I do not prescribe / I do not recommend
Cegedim CZ, Cegedim Strategic Data 2007
Q. 5: What are your main reasons to prescribe/recommend Smecta. (most often named)
(% base – Smecta is first choice anti-diarrhoeal)NTOTAL = 98
GlaxoSmithKline – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007
Q. 6A: Will you estimate how many patients with diarrhoea do you monthly prescribe with Smecta on the average.
Ipsen – Medibus PED4
average number of patients per month median – the middle value
(base for average – total sample)NTOT = 98, NLC = 36, NMC = 39, NBC = 23
Cegedim CZ, Cegedim Strategic Data 2007
Q. 6B: Will you estimate to how many patients with diarrhoea do you monthly recommend Smecta on the average.
Ipsen – Medibus PED4
average number of patients per month median – the middle value
(base for average – total sample)NTOT = 98, NBC = 36, NMC = 39, NBC = 23
Cegedim CZ, Cegedim Strategic Data 2007Ipsen – Medibus PED4
Analysis II. q. 6: Rate of prescription and recommendation of Smecta.
(% base – total sample)NTOT = 98, NBC = 36, NMC = 39, NBC = 23
Smecta - total
Cegedim CZ, Cegedim Strategic Data 2007Ipsen – Medibus PED4
Analysis II. q. 6: Rate of prescription and recommendation of Smecta.
(% base – total sample)
Smecta - prescribing Smecta - recommending
TOTAL (N = 98) LITTLE CITY (N = 36)
MIDDLE CITY (N = 39) BIG CITY (N = 23)
Cegedim CZ, Cegedim Strategic Data 2007Ipsen – Medibus PED4
Q. 7A: Will you estimate at which % of patients using Smecta do you continue with treatment with other preparations – e.g. with probiotics and at which % of patients you do not continue with additional treatment.
(base for average % - total sample)
I continue with additional treatment I do not continue with additional treatment
TOTAL (N = 98) LITTLE CITY (N = 36)
MIDDLE CITY (N = 39) BIG CITY (N = 23)
Cegedim CZ, Cegedim Strategic Data 2007
Q. 7B: If you continue with additional treatment at patients using Smecta, which particular preparations do you prescribe/recommend after Smecta? (the most often named)
(% base – continue with treatment with other preparations)NTOTAL = 90
Ipsen – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007
Q. 8A: Try please to specify – when, at which cases, at what kind of patients do you use Smecta. (most often named)
(% base – total sample)NTOTAL = 98
Ipsen – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007
Q. 8B: Try please to specify – when, at which cases, at what kind of patients do you use probiotics. (most often named)
(% base – total sample)NTOTAL = 98
Ipsen – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007
Q. 9A: How do you usually solve rotavirus infections? (most often named)
(% base – total sample)NTOTAL = 98
Ipsen – Medibus PED4
Cegedim CZ, Cegedim Strategic Data 2007
Q. 9B: If you prescribe your patients with rotavirus infections with pharmacological treatment, which preparations do you most often use? (most often named)
(% base – total sample)NTOTAL = 98
Ipsen – Medibus PED4